Perrigo Seeks To Slow Rivals’ Private-Label Prevacid Launches
This article was originally published in The Tan Sheet
You may also be interested in...
Perrigo Squares Off With Dr. Reddy’s In Lansoprazole Launch
U.S. FDA denied Perrigo’s petition that had sought to block Dr. Reddy’s ANDA for generic Prevacid 24HR because it used bioequivalence data for the proton pump inhibitor’s Rx version. Competition between the firms is intensifying as Dr. Reddy’s expands its U.S. OTC presence.
Perrigo Squares Off With Dr. Reddy’s In Lansoprazole Launch
U.S. FDA denied Perrigo’s petition that had sought to block Dr. Reddy’s ANDA for generic Prevacid 24HR because it used bioequivalence data for the proton pump inhibitor’s Rx version. Competition between the firms is intensifying as Dr. Reddy’s expands its U.S. OTC presence.
Perrigo Squares Off With Dr. Reddy’s In Lansoprazole Launch
FDA denied Perrigo’s petition that had sought to block Dr. Reddy’s ANDA for generic Prevacid 24HR because it used bioequivalence data for the proton pump inhibitor’s Rx version. Competition between the firms is intensifying as Dr. Reddy’s expands its U.S. OTC presence.